HTGC
Hercules Capital, Inc. NYSE Listed Jun 9, 2005$16.61
-1.63%
vs $16.88
Mkt Cap $3.1B
52w Low $13.70
48.7% of range
52w High $19.67
50d MA $15.72
200d MA $16.53
P/E (TTM)
8.2x
EV/EBITDA
12.7x
P/B
1.4x
Debt/Equity
1.0x
ROE
15.3%
P/FCF
-7.7x
RSI (14)
63.00
ATR (14)
$0.32
Beta
0.78
50d MA
$15.72
200d MA
$16.53
Avg Volume
1.4M
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
CIK (SEC)
Phone
650 289 3060
400 Hamilton Avenue · Palo Alto, CA 94301 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | AMC | 0.50 | 0.50 | +0.0% | 15.94 | +2.9% | +3.0% | +2.4% | +0.4% | — | — | — |
| May 5, 2026 | AMC | 0.47 | 0.48 | +2.1% | 16.57 | +2.3% | -0.8% | -0.2% | -1.5% | -0.6% | -0.4% | — |
| Feb 12, 2026 | AMC | 0.48 | 0.48 | +0.0% | 16.60 | -3.3% | -6.1% | +1.7% | +0.8% | -1.9% | -1.4% | — |
| Oct 30, 2025 | AMC | 0.48 | 0.49 | +2.1% | 17.59 | -0.5% | +1.9% | -0.6% | +0.9% | +0.6% | -1.7% | — |
| Jul 31, 2025 | AMC | 0.47 | 0.50 | +6.4% | 18.76 | +1.3% | +2.1% | +1.1% | +0.7% | +0.2% | -1.0% | — |
| May 1, 2025 | AMC | 0.46 | 0.45 | -2.2% | 17.81 | -1.3% | -0.9% | -1.0% | -0.1% | -1.1% | +1.8% | — |
| Feb 13, 2025 | AMC | 0.51 | 0.49 | -3.9% | 21.05 | -2.6% | +1.0% | +2.0% | +1.4% | -1.3% | -1.1% | — |
| Oct 30, 2024 | AMC | 0.51 | 0.51 | +0.0% | 19.90 | -0.5% | -0.7% | -2.7% | -0.5% | +0.0% | +3.5% | — |
| Aug 1, 2024 | AMC | 0.51 | 0.51 | +0.0% | 21.31 | -2.8% | -11.7% | -5.8% | +4.1% | -1.8% | +1.8% | — |
| May 2, 2024 | AMC | 0.50 | 0.50 | +0.0% | 19.30 | +0.6% | +0.7% | +1.3% | +0.4% | -0.3% | +0.8% | — |
| Feb 15, 2024 | AMC | 0.50 | 0.56 | +12.0% | 17.74 | +1.5% | +4.8% | -0.7% | -0.1% | +1.5% | -0.5% | — |
| Nov 2, 2023 | AMC | 0.50 | 0.52 | +4.0% | 16.10 | +0.9% | -1.4% | +0.8% | -1.3% | +0.8% | -0.6% | — |
| Aug 3, 2023 | AMC | 0.49 | 0.53 | +8.2% | 17.08 | +2.8% | +3.9% | +1.5% | -5.2% | -0.1% | +0.4% | — |
| May 4, 2023 | AMC | 0.46 | 0.47 | +2.2% | 12.54 | +2.5% | +4.5% | +3.9% | -2.2% | +2.1% | -0.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.67 | $15.85 | +1.1% | +0.9% | -2.9% | +1.0% | -0.2% | +1.1% |
| Apr 16 | Keefe, Bruyette & Woods | Maintains | Outperform → Outperform | — | $15.68 | $15.74 | +0.4% | -0.3% | +2.0% | -0.3% | -1.6% | +0.9% |
| Apr 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.18 | $15.10 | -0.5% | -0.4% | -0.9% | -1.6% | +1.4% | +2.2% |
| Mar 13 | UBS | Maintains | Neutral → Neutral | — | $14.04 | $14.13 | +0.6% | +0.0% | +0.1% | +3.2% | -0.3% | -0.3% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $16.60 | $16.06 | -3.3% | -6.1% | +1.7% | +0.8% | -1.9% | -1.4% |
| Feb 13 | Piper Sandler | Downgrade | Overweight → Neutral | — | $16.60 | $16.06 | -3.3% | -6.1% | +1.7% | +0.8% | -1.9% | -1.4% |
| Feb 13 | Keefe, Bruyette & Woods | Maintains | Outperform → Outperform | — | $16.60 | $16.06 | -3.3% | -6.1% | +1.7% | +0.8% | -1.9% | -1.4% |
| Nov 4 | Compass Point | Upgrade | Neutral → Buy | — | $17.81 | $17.87 | +0.3% | +0.9% | +0.6% | -1.7% | +1.2% | -0.8% |
| Oct 14 | UBS | Maintains | Neutral → Neutral | — | $17.13 | $16.95 | -1.1% | +1.7% | -0.2% | -1.3% | +0.6% | +1.3% |
| Oct 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.71 | $17.60 | -0.6% | -3.7% | -2.1% | +2.6% | +1.7% | -0.2% |
| Aug 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $19.15 | $19.17 | +0.1% | +1.1% | +0.7% | +0.2% | -1.0% | +0.9% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.76 | $19.00 | +1.3% | +2.1% | +1.1% | +0.7% | +0.2% | -1.0% |
| Jul 16 | UBS | Maintains | Neutral → Neutral | — | $19.03 | $19.05 | +0.1% | +1.0% | +1.1% | -0.5% | -1.1% | +0.7% |
| Apr 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.91 | $17.92 | +0.1% | +1.0% | +0.3% | -1.4% | -0.5% | -0.9% |
| Apr 17 | UBS | Maintains | Neutral → Neutral | — | $17.23 | $17.23 | +0.0% | +1.8% | -2.2% | +1.5% | +1.1% | +1.8% |
| Apr 8 | Keefe, Bruyette & Woods | Maintains | Outperform → Outperform | — | $16.60 | $17.35 | +4.5% | -2.2% | +7.7% | -3.8% | +0.0% | +1.5% |
| Apr 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.60 | $17.35 | +4.5% | -2.2% | +7.7% | -3.8% | +0.0% | +1.5% |
| Feb 19 | Compass Point | Maintains | Neutral → Neutral | — | $21.70 | $21.60 | -0.5% | +1.4% | -1.3% | -1.1% | -0.3% | -0.8% |
| Feb 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.05 | $20.50 | -2.6% | +1.0% | +2.0% | +1.4% | -1.3% | -1.1% |
| Jan 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $20.12 | $20.29 | +0.8% | +0.5% | -1.0% | -0.2% | -1.3% | +0.7% |
| Dec 12 | Keefe, Bruyette & Woods | Upgrade | Market Perform → Outperform | — | $19.40 | $19.74 | +1.8% | +0.2% | -0.2% | -0.9% | -0.3% | -2.0% |
| Dec 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.91 | $18.98 | +0.4% | +3.2% | -0.6% | +1.3% | -1.2% | +0.2% |
| Oct 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $20.14 | $20.01 | -0.6% | -0.7% | -0.5% | -0.7% | -2.7% | -0.5% |
| Aug 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.31 | $20.72 | -2.8% | -11.7% | -5.8% | +4.1% | -1.8% | +1.8% |
| Jul 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.31 | $21.43 | +0.6% | +1.7% | -0.5% | -1.2% | -11.7% | -5.8% |
| Jul 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $21.13 | $21.25 | +0.6% | +1.4% | -0.6% | +1.7% | -0.5% | -1.2% |
| Jul 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $20.50 | $20.60 | +0.5% | +2.7% | +0.2% | +0.5% | +0.8% | +0.2% |
| May 3 | Keefe, Bruyette & Woods | Maintains | Market Perform → Market Perform | — | $19.30 | $19.42 | +0.6% | +0.7% | +1.3% | +0.4% | -0.3% | +0.8% |
| May 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $19.30 | $19.42 | +0.6% | +0.7% | +1.3% | +0.4% | -0.3% | +0.8% |
| May 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $19.30 | $19.42 | +0.6% | +0.7% | +1.3% | +0.4% | -0.3% | +0.8% |
| May 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $19.30 | $19.42 | +0.6% | +0.7% | +1.3% | +0.4% | -0.3% | +0.8% |
| Apr 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.41 | $18.26 | -0.8% | -0.4% | +0.4% | -1.3% | -1.2% | +0.2% |
| Mar 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.25 | $18.30 | +0.3% | -0.2% | +0.8% | +0.4% | -1.3% | +0.5% |
| Feb 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.74 | $18.00 | +1.5% | +4.8% | -0.7% | -0.1% | +1.5% | -0.5% |
| Feb 16 | Keefe, Bruyette & Woods | Maintains | Market Perform → Market Perform | — | $17.74 | $18.00 | +1.5% | +4.8% | -0.7% | -0.1% | +1.5% | -0.5% |
| Jan 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.56 | $17.59 | +0.2% | +0.5% | +0.9% | -2.8% | -0.7% | +0.5% |
| Jan 16 | Compass Point | Downgrade | Buy → Neutral | — | $17.58 | $17.28 | -1.7% | -3.6% | -0.2% | +0.1% | +0.3% | +1.9% |
| Dec 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.22 | $16.20 | -0.1% | -0.1% | +0.3% | +1.0% | +1.5% | +1.6% |
| Nov 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.10 | $16.25 | +0.9% | -1.4% | +0.8% | -1.3% | +0.8% | -0.6% |
| Aug 30 | Compass Point | Upgrade | Neutral → Buy | — | $16.33 | $16.63 | +1.8% | +1.3% | -0.5% | -0.5% | -1.9% | -1.4% |
| Aug 11 | JMP Securities | Maintains | Outperform → Outperform | — | $17.13 | $17.21 | +0.5% | +0.1% | -0.1% | -0.9% | +0.1% | -3.9% |
| Aug 4 | Oppenheimer | Maintains | Perform → Perform | — | $17.08 | $17.56 | +2.8% | +3.9% | +1.5% | -5.2% | -0.1% | +0.4% |
| Aug 4 | Keefe, Bruyette & Woods | Upgrade | Underperform → Market Perform | — | $17.08 | $17.56 | +2.8% | +3.9% | +1.5% | -5.2% | -0.1% | +0.4% |
| May 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $13.10 | $13.26 | +1.2% | +3.9% | -2.2% | +2.1% | -0.1% | -1.8% |
| May 5 | Keefe, Bruyette & Woods | Maintains | Underperform → Underperform | — | $12.54 | $12.85 | +2.5% | +4.5% | +3.9% | -2.2% | +2.1% | -0.1% |
| May 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $12.54 | $12.85 | +2.5% | +4.5% | +3.9% | -2.2% | +2.1% | -0.1% |
| Apr 6 | Piper Sandler | Upgrade | Neutral → Overweight | — | $12.49 | $12.88 | +3.1% | +0.0% | -0.9% | +0.4% | +0.2% | +2.2% |
| Mar 13 | JMP Securities | Maintains | Market Outperform → Outperform | — | $12.29 | $11.14 | -9.4% | -5.9% | +3.4% | -3.3% | +4.2% | -1.2% |
| Mar 13 | Keefe, Bruyette & Woods | Downgrade | Market Perform → Underperform | — | $12.29 | $11.14 | -9.4% | -5.9% | +3.4% | -3.3% | +4.2% | -1.2% |
| Feb 21 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $16.24 | $16.13 | -0.7% | -4.0% | +0.3% | +0.8% | +0.6% | +0.9% |
No insider trades available.
8-K · 1.01
! Medium
Hercules Capital, Inc. -- 8-K 1.01: Underwriting / Securities
Jul 24
8-K · 2.02
!! High
Hercules Capital, Inc. -- 8-K 2.02: Earnings Results
Jul 21
8-K · 1.01
!! High
4D Molecular Therapeutics, Inc. -- 8-K 1.01: Material Agreement
4D Molecular Therapeutics secured $200 million in financing from Hercules Capital through a loan and security agreement, providing substantial capital for clinical development and operations.
Jun 29
8-K · 1.01
! Medium
Dyne Therapeutics, Inc. -- 8-K 1.01: Financing / Debt Agreement
Dyne Therapeutics secured a $400 million financing agreement with Hercules Capital, providing significant capital to fund its clinical development and operations.
Jun 17
8-K
Hercules Capital, Inc. -- 8-K Filing
Hercules Capital appointed Olson as Interim Chief Financial Officer, bringing finance leadership experience and CPA credentials to guide the company's financial operations.
May 4
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary describes only technical XBRL metadata and form structure rather than actual company events or financial disclosures that would impact stock valuations.
Apr 1
8-K
enGene Therapeutics Inc. -- 8-K Filing
enGene Therapeutics announced Q1 2026 results and expects to present updated data from its LEGEND trial for bladder cancer treatment at an upcoming spring medical conference.
Mar 9
8-K · 5.02
!!! Very High
MoonLake Immunotherapeutics Class A -- 8-K 5.02: Executive Change
MoonLake Immunotherapeutics (MLTX) appointed an interim chair and two new independent directors while Simon Sturge resigned, signaling potential governance restructuring that investors should monitor for strategic implications.
Feb 23
8-K
Hercules Capital, Inc. -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it appears to contain only signature and administrative sections without disclosing a specific corporate event or financial transaction affecting investor interests.
Feb 12
8-K · 1.01
! Medium
Hercules Capital, Inc. -- 8-K 1.01: Underwriting / Securities
Hercules Capital established a tenth supplemental indenture with Goldman Sachs, likely modifying debt terms or issuing new securities to strengthen its capital structure and financing flexibility.
Feb 10
8-K · 1.01
!! High
Maze Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Maze Therapeutics secured $40 million in initial term loan funding from Hercules Capital, providing capital for operations and development while obligating the company to repay debt.
Feb 4
8-K · 8.01
!! High
Hercules Capital, Inc. -- 8-K 8.01: Material Event / Announcement
Hercules Capital reported approximately $20 million in realized gains for Q4 2025, with NAV per share rising $0.05 to $0.11 as of September 30, 2025.
Feb 3
8-K · 1.01
!! High
Replimune Group, Inc. -- 8-K 1.01: Material Agreement
Replimune secured an additional $30 million in funding from Hercules Capital through a loan amendment, providing financial flexibility for the biotech company's clinical development programs.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 2,228,346 | $42M | Reduced | Dec 2025 |
| 2 | Ubs Group Ag | 2,493,992 | $37M | Added | Mar 2026 |
| 3 | Two Sigma Investments, Lp | 2,324,859 | $34M | Added | Mar 2026 |
| 4 | Qube Research & Technologies Ltd | 2,235,750 | $33M | Added | Mar 2026 |
| 5 | D.e. Shaw & Co | 1,548,960 | $23M | Added | Mar 2026 |
| 6 | Franklin Resources Inc | 1,135,489 | $17M | Added | Mar 2026 |
| 7 | Advisors Capital Management, Llc | 828,258 | $16M | Added | Dec 2025 |
| 8 | Millennium Management | 985,160 | $15M | Reduced | Mar 2026 |
| 9 | Jpmorgan Chase & Co | 878,600 | $12M | Added | Mar 2026 |
| 10 | Citadel Advisors Llc | 815,385 | $12M | Added | Mar 2026 |
| 11 | Wells Fargo & Company/mn | 749,207 | $11M | New | Mar 2026 |
| 12 | Royal Bank Of Canada | 496,406 | $7M | Reduced | Mar 2026 |
| 13 | Hrt Financial Lp | 495,278 | $7M | Added | Mar 2026 |
| 14 | Raymond James Financial Inc | 476,568 | $7M | Reduced | Mar 2026 |
| 15 | Jane Street Group, Llc | 358,937 | $7M | Added | Dec 2025 |
| 16 | Susquehanna International Group, Llp | 442,571 | $7M | Added | Mar 2026 |
| 17 | D.a. Davidson & Co. | 309,211 | $6M | Added | Dec 2025 |
| 18 | Neuberger Berman Group Llc | 301,673 | $4M | — | Mar 2026 |
| 19 | Commonwealth Equity Services, Llc | 220,042 | $4M | Reduced | Dec 2025 |
| 20 | Fj Capital Management Llc | 277,666 | $4M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 14
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | VanEck BDC Income ETF | 2,565,669 | $38M | Mar 2026 |
| 2 | Putnam BDC Income ETF | 994,038 | $18M | Jan 2026 |
| 3 | FT Confluence BDC & Specialty Finance Income ETF | 229,506 | $4M | May 2026 |
| 4 | WisdomTree Private Credit and Alternative Income Fund | 112,783 | $2M | May 2026 |
| 5 | Invesco Global Listed Private Equity ETF | 85,726 | $2M | Jan 2026 |
| 6 | Sound Enhanced Fixed Income ETF | 77,178 | $1M | May 2026 |
| 7 | Small Cap Value Fund | 62,437 | $922K | Mar 2026 |
| 8 | Virtus Private Credit Strategy ETF | 34,228 | $634K | Jan 2026 |
| 9 | WHITEWOLF Publicly Listed Private Equity ETF | 33,461 | $620K | Jan 2026 |
| 10 | Mercer Opportunistic Fixed Income Fund | 30,461 | $450K | Mar 2026 |
| 11 | ProShares Global Listed Private Equity ETF | 28,335 | $403K | Feb 2026 |
| 12 | LOW-DURATION BOND FUND | 375,000 | $368K | Mar 2026 |
| 13 | Sit Small Cap Dividend Growth Fund | 24,675 | $364K | Mar 2026 |
| 14 | Longview Advantage ETF | 4,500 | $64K | Feb 2026 |
Valuation
Market Cap
$3.11B
Enterprise Value
$5.53B
P/E (TTM)
8.24x
Forward P/E
8.51x
PEG Ratio
0.56x
P/B
1.35x
P/S
5.58x
P/FCF
-7.72x
EV/EBITDA
12.66x
Shares Out
194.8M
Financials (TTM)
Revenue
$579.8M
Net Income
$383.2M
EBITDA
$437.0M
Free Cash Flow
-$425.9M
Op Cash Flow
-$425.8M
EPS Basic
$1.90
EPS Diluted
$1.99
EPS Forward
$1.95
Gross Margin
89.9%
Op Margin
75.3%
Net Margin
66.1%
Balance Sheet
Total Assets
$4.58B
Total Liab.
$2.37B
Total Equity
$2.22B
Cash
$56.9M
LT Debt
$2.30B
Book Value/Sh
$12.26
Debt/Equity
1.04x
Current Ratio
1.44
Quick Ratio
1.44
Returns & Growth
ROE
15.3%
ROA
7.4%
ROIC
835.3%
Rev Growth YoY
+27.0%
EPS Growth YoY
+18.0%
Price Returns
2W
+4.6%
1M
+5.2%
3M
+1.9%
6M
+3.4%
12M
-13.4%
Technicals
52W High
$19.67
52W Low
$13.70
50d MA
$15.72
200d MA
$16.53
RSI (14)
63.00
ATR (14)
$0.32
Beta
0.78
Avg Volume
1.4M
Dividends
Div Rate
$1.80
Div Yield
11.1%
Frequency
4
Ex-Div Date
Feb 25, 2026
Analyst Price Targets
Consensus
$18.92
High
$19.75
Low
$17.50
Median
$19.50
Data updated apr 25, 2026 2:13pm
· Source: financialmodelingprep.com